Genomic characterization of chikungunya virus during the large 2025 outbreak in Sri Lanka reveals emergence of a distinct Indian Ocean lineage strain

A major outbreak of Chikungunya in Sri Lanka has been linked to a new version of the virus. Scientists used advanced DNA sequencing to find specific mutations. These changes might help the virus spread more easily through mosquitoes and evade the body's immune system.

The Problem

Chikungunya virus (CHIKV) is an arbovirus (a virus transmitted to humans through the bite of infected arthropods like mosquitoes). It causes debilitating joint pain and high fever. Its transmission dynamics are notoriously difficult to predict. This is because the virus is constantly evolving.

Current public health strategies often rely on broad surveillance. However, they frequently fail to identify specific molecular shifts. Such shifts can turn a low-level endemic presence into a massive outbreak. In Sri Lanka, the virus circulated at very low levels for nearly two decades. The sudden re-emergence in 2025 presented a critical question. Was this a seasonal surge of known strains? Or had the virus undergone a fundamental genetic shift? Such a shift could alter its ability to infect humans or move between mosquito vectors. Without genomic resolution, health authorities cannot know if existing vector control strategies will remain effective. They also cannot know if developing vaccines will work against the new dominant strain.

How It Works

To resolve this, the researchers employed a high-resolution genomic surveillance pipeline. Their approach relied on three core methodological pillars:

1. High-Depth Sequencing: The team recruited 268 acute febrile patients. They screened them using quantitative PCR (a method to detect specific viral RNA) to identify CHIKV-positive cases. They then selected 20 samples with high viral loads. Specifically, they chose those with cycle threshold (Ct) values <20. They used Oxford Nanopore Technologies (ONT) for whole-genome sequencing. This allowed them to reconstruct the entire viral genome.
2. Phylogenetic and Phylodynamic Reconstruction: The authors used a Bayesian statistical framework implemented in BEAST to trace the virus's history. This involves calculating the "time of most recent common ancestor" (tMRCA). This is the point in time where all sequences in a group share a single progenitor. They also modeled how the virus moved geographically over time.
3. Structural Mapping: The researchers mapped amino acid changes onto the physical 3-D structures of viral proteins. They overlaid mutations onto known models of the E1 and E2 envelope proteins. This helped them see where mutations sit in relation to the "keys" the virus uses to enter human cells.

As shown in, this allowed them to place the Sri Lankan outbreak within the broader family tree of the virus.

The 2025 strains formed a distinct, unified group (a monophyletic clade). This group was separate from both historical strains and contemporary outbreaks in Brazil or China.

Numbers

The scale of the evolutionary shift is captured in the molecular signatures identified. The 2025 Sri Lankan outbreak was driven by a specific sub-lineage of the Indian Ocean Lineage (IOL). This lineage carries a unique set of mutations.

The authors report that the 2025 strains are characterized by key substitutions in the structural proteins: E1:K211E and E2:V264A. These are not mere statistical noise. They represent a departure from the older 2006–2008 strains. Other global outbreaks, such as those in China, are driven by the A226V mutation. That mutation favors transmission by the Aedes albopictus mosquito. In contrast, the Sri Lankan mutations are associated with enhanced fitness in Aedes aegypti. This is the primary mosquito vector in urban environments.

The temporal analysis provides a timeline for this emergence. The authors estimate the tMRCA for the Sri Lankan clade to be February 2024. The 95% highest posterior density (a statistical range of certainty) was August 2023 to August 2024. This suggests the virus had been circulating in an unsampled capacity for months. The mean nucleotide substitution rate was $8.11 \times 10^{-4}$ substitutions per site per year. This metric quantifies the speed of the virus's evolutionary clock.

What's Missing

While the study provides a high-resolution snapshot, it has notable blind spots.

First, the researchers focused sequencing on samples with low Ct values (<20). This means they targeted patients with the highest concentrations of the virus. While this ensures high-quality data, it creates a selection bias. The study may have missed the "genetic tail." These are lower-intensity variations that circulate in the broader population. Such variations could reveal how the virus transitions to explosive outbreaks.

Second, the study is geographically constrained to an urban cohort. Mosquito populations and human behaviors vary between cities and rural areas. Therefore, the genomic diversity captured here might not reflect the true breadth of the virus's movement.

Finally, the most significant gap is functional. The authors use structural modeling to predict outcomes. They suggest mutations like E2:R198 might help the virus evade antibodies . They also suggest others might improve receptor binding at the MXRA8 interface. However, these are computational inferences. Until these mutations are tested in a wet lab, the biological consequences remain hypotheses.

Should You Prototype This

If you are a public health official or a vaccine researcher, the answer is yes, but with caution.

The identification of the E1:K211E and E2:V264A mutations should trigger a shift in surveillance. Priorities should move toward Aedes aegypti-heavy urban centers. For those developing CHIKV vaccines, this paper serves as a warning. The "target" is moving. A vaccine designed against the 2006 strains may face reduced efficacy against this new sub-lineage. This is due to mutations mapped near neutralizing antibody epitopes (regions where antibodies bind to the virus) .

However, do not treat these structural findings as absolute truth. Use the genomic data as a roadmap for functional validation experiments. Do not use them as a finished blueprint for clinical intervention.

Figures from the paper